Rhopressa (Netarsudil Mesylate) Patent Expiration, LOE Window & CMS Spending

Rhopressa (Netarsudil Mesylate) by Novartis: FDA Orange Book core substance LOE 2034-03-14, 0 AB generics, $178.0M 2024 CMS Part D & Medicaid spend.

Regulatory & Reimbursement Dimension Verified Value
Consolidated SponsorNovartis
FDA Application & PathwayN208254 (NDA)
Exclusivity / Cliff HorizonMid-Term Protection (2031-2035)
Core Active-Ingredient LOE Date2034-03-14
Last Listed Patent or Exclusivity Date2034-03-14
Orange Book Patents (*PED Extensions)15 patents (0 *PED)
Active AB-Rated Generic Competitors0
2024 CMS Total Public Spend$178.0M
2024 Medicare Part D Spend$168.0M
2024 Medicaid Spend$10.0M
Reported Wholesale Price Change (CA SB 17)0 statutory filings in 2023 to 2026 panel

Related Filings Across Meru Platforms

Verified cross-ledger federal filings for Novartis across sibling Meru public-data platforms.